Pacific Biosciences of California financials
$1.83+7.02%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $160.0M | $154.0M | $200.5M | $128.3M | $130.5M | $78.9M | $90.9M | $78.6M | $93.5M | $90.7M |
| Gross profit | $45.8M | $37.3M | $52.8M | $49.0M | $58.9M | $32.6M | $34.6M | $25.1M | $34.7M | $44.2M |
| Gross margin | 28.6% | 24.2% | 26.3% | 38.2% | 45.1% | 41.3% | 38.0% | 31.9% | 37.1% | 48.7% |
| Operating income | -$553.9M | -$474.3M | -$334.5M | -$307.2M | -$210.4M | -$104.4M | -$100.5M | -$101.0M | -$89.8M | -$71.2M |
| Net income | -$546.4M | -$309.9M | -$306.7M | -$314.2M | -$181.2M | $29.4M | -$84.1M | -$102.6M | -$92.2M | -$74.4M |
| Net margin | −341.5% | −201.2% | −153.0% | −244.9% | −138.9% | 37.3% | −92.6% | −130.4% | −98.6% | −82.0% |
| Diluted EPS | $-1.82 | $-1.59 | $-1.21 | $-1.40 | $-0.89 | $0.17 | $-0.55 | $-0.76 | $-0.87 | $-0.83 |
| EBITDA | -$156.4M | -$248.6M | -$305.7M | -$294.4M | -$166.6M | -$95.1M | -$90.6M | -$93.8M | -$81.3M | -$67.4M |
| Operating cash flow | -$111.2M | -$206.1M | -$259.2M | -$263.2M | -$111.2M | $19.5M | -$78.3M | -$66.4M | -$67.5M | -$67.9M |
| Free cash flow | -$113.9M | -$212.2M | -$268.0M | -$280.0M | -$117.1M | $18.5M | -$81.1M | -$68.3M | -$78.0M | -$76.1M |
| Diluted shares | 300.0M | 288.4M | 253.6M | 224.6M | 204.1M | 175.0M | 152.5M | 135.1M | 105.7M | 89.1M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $63.7M | $55.4M | $179.9M | $325.1M | $460.7M | $81.6M |
| Short-term investments | $215.8M | $334.6M | $451.5M | $447.2M | $583.7M | $237.2M |
| Total debt | $645.4M | $647.5M | $892.2M | $896.7M | $896.1M | $0.00 |
| Total assets | $784.1M | $1.26B | $1.75B | $1.77B | $2.01B | $414.0M |
| Total liabilities | $778.7M | $753.9M | $1.04B | $1.20B | $1.22B | $78.5M |
| Shareholders' equity | $5.3M | $506.6M | $701.3M | $562.9M | $791.0M | $335.5M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology